Teva Pharmaceutical Industries Ltd. (TEVA)

12.88
0.14 1.08
NYSE : Health Technology
Prev Close 13.02
Open 13.02
Day Low/High 12.74 / 13.04
52 Wk Low/High 6.07 / 13.76
Volume 8.65M
Avg Volume 17.29M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 14.33B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Standing its Ground

The market stood its ground and then some today:   * A buy program was the last program standing. * The Nasdaq regained strength. Ns over Ss and Rs. * Financials paused (life insurance particularly weak as spin off not well received) - though rallie...

Are You Brave Enough to Buy Low?

Are You Brave Enough to Buy Low?

'Buy low and sell high' is easier said than done, but you can fight your fear with TEVA.

Action Alerts PLUS: There's Strength in (Earnings) Numbers

Action Alerts PLUS: There's Strength in (Earnings) Numbers

Callout: Results and guidance lift markets, dodging D.C. drama.

Bad Drugs

Further Teva losses are plaguing Allergan today.

Teva Cut to Market Perform at Bernstein

Closing Bell: Another Record for Dow Stretches Streak Into Day Seven; Avon Tumbles

Closing Bell: Another Record for Dow Stretches Streak Into Day Seven; Avon Tumbles

Negligible gains for the Dow Jones Industrial Average were enough to put it at records.

Confusion Reigns in the Market

Confusion Reigns in the Market

News on Russia probe weighs on stocks.

Jim Cramer on Tesla, Take-Two Interactive, Yum! Brands, Lam Research, Teva and Costco

Jim Cramer on Tesla, Take-Two Interactive, Yum! Brands, Lam Research, Teva and Costco

Jim Cramer analyzes Thursday's market movers.

Teva Pharmaceuticals Is Probably the Weakest of the Group, Jim Cramer Says

Teva Pharmaceuticals Is Probably the Weakest of the Group, Jim Cramer Says

The stock is getting hit.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Technology Might Be About to Change the Healthcare Industry Forever

Technology Might Be About to Change the Healthcare Industry Forever

Technology might be about to change the healthcare industry forever, or at least according to Teva Pharmaceutical's CEO.

These Stocks Are Changing Course

These Stocks Are Changing Course

Bullish and bearish reversals for this week.

Teva Ready for Higher Prices

Teva Ready for Higher Prices

The money flow has turned positive.

Uber's Quarterly Loss was a Staggering $708 Million, Key Exec Leaves

Uber's Quarterly Loss was a Staggering $708 Million, Key Exec Leaves

Uber's first quarter loss was less than the $991 million loss reported 3 months ago.

Teva Pharmaceutical Is Ready for a Tradable Rally

Teva Pharmaceutical Is Ready for a Tradable Rally

Prices are extended on the downside.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Teva Pharmaceutical Looks Vulnerable to Further Losses

Teva Pharmaceutical Looks Vulnerable to Further Losses

It will probably take a close above $38 to turn the chart more bullish.

Go With Allergan, Celgene and 'Big Mo'

Go With Allergan, Celgene and 'Big Mo'

These two large-cap drug giants should be core parts of any well-diversified portfolio.

Closing Bell: Apple Rallies to New Highs; U.S. Stocks End at Fresh Records for Day Three

Closing Bell: Apple Rallies to New Highs; U.S. Stocks End at Fresh Records for Day Three

Wall Street rallies to new records as leftover goodwill from Friday's rally pushes stocks to new heights.

Cramer: If Trump Is So Bad for Stocks, Where's the Correction?

Cramer: If Trump Is So Bad for Stocks, Where's the Correction?

Yes, he's unpredictable, but is that a reason to sell?

JIm Cramer: Investors Should Be Cautious With Teva Pharmaceutical

JIm Cramer: Investors Should Be Cautious With Teva Pharmaceutical

Jim Cramer discusses why investors should be cautious after Teva Pharmaceutical's CEO left the company.

Teva Pharmaceuticals CEO Steps Down After a Series of Missteps

Teva Pharmaceuticals CEO Steps Down After a Series of Missteps

The CEO of Teva Pharmaceuticals has left the company, which has faced a series of challenges.

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

Three Health-Care Growth Plays

Three Health-Care Growth Plays

Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.